Based on preclinical efficacy data of ixazomib [33] and given it’s favorable toxicity profile [29], we aimed to evaluate the stem cell mobilizing efficacy of G-CSF combined with ixazomib in MM patients undergoing HDCT and ASCT. Here, CSF3 is linked to Miyoshi myopathy.